LQDA · Liquidia Corp
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $450.91M | $158.32M | $14M | $17.49M | $15.94M | $12.85M | $739.63K | $8.07M | |
| $5.93M | — | $5.88M | $2.89M | $2.86M | $3.02M | $237.71K | — | |
| $8.22M | — | $8.12M | $14.6M | $13.08M | $9.83M | $501.92K | — | |
| — | — | 58% | 83.49% | 82.06% | 76.48% | 67.86% | — | |
| $56.04M | $39.28M | $47.84M | $43.24M | $19.44M | $20.52M | $32.22M | $40.49M | |
| $91.38M | — | $81.57M | $44.74M | $32.41M | $23.11M | $27.37M | $13.6M | |
| $192.66M | $157.18M | $81.57M | $44.74M | — | — | — | — | |
| — | $200K | $300K | $300K | $700K | $1.1M | — | — | |
| $1.67M | $1.53M | $2.2M | $2.18M | $3.65M | $5.61M | $3.13M | $2.57M | |
| $282.33M | $209.7M | $135.29M | $90.87M | $54.71M | $46.65M | $59.83M | $54.9M | |
| $168.58M | -$51.38M | -$121.29M | -$73.38M | -$38.77M | -$33.8M | -$59.09M | -$46.82M | |
| — | -32.45% | -866.63% | -419.62% | -243.3% | -262.95% | -7989.03% | -580.07% | |
| $170.25M | -$49.85M | -$119.1M | -$71.21M | -$35.12M | -$28.19M | -$55.96M | -$44.26M | |
| $26.63M | $24.17M | $14.65M | $6.27M | $2.34M | $762K | $858K | $1.37M | |
| $7.56M | $6.62M | $7.65M | $3.47M | $1.09M | $33K | $184.36K | $613.72K | |
| -$19.07M | -$17.55M | -$7M | -$5.12M | -$2.25M | -$782K | -$673.64K | -$759.91K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $138.61M | -$68.92M | -$128.29M | -$78.5M | -$41.02M | -$34.58M | -$59.76M | -$47.58M | |
| — | -43.53% | -916.63% | -448.89% | -257.39% | -269.03% | -8080.11% | -589.48% | |
| USD/shares | $1.58 | -$0.80 | -$1.63 | -$1.21 | -$0.67 | -$0.70 | -$1.76 | — |
| USD/shares | $1.40 | -$0.80 | -$1.63 | -$1.21 | -$0.67 | -$0.70 | -$1.76 | -$2.57 |
| shares | — | 86.06M | 78.71M | 64.99M | 60.96M | 49.68M | 33.89M | 18.48M |
| shares | — | 86.06M | 78.71M | 64.99M | 60.96M | 49.68M | 33.89M | 18.48M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 35 similar-size Drug Manufacturers - Specialty & Generic companies (of 98 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | $158,320,000 | $13,996,000 | $17,488,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Product | $148,288,000 | — | — | — | — |
| Service | $10,032,000 | $13,996,000 | $17,488,000 | $739,628 | $0 |
| Collaboration | — | — | — | $0 | $8,072,120 |
| Research and Development Services | — | — | — | $0 | $200 |
| Royalty | — | — | — | $0 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -$51,376,000 | -$121,294,000 | -$73,384,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -32.5% | -866.6% | -419.6% |